The Vaccine Adverse Event Reporting System (VAERS) form Version 2.0 (proposed)

Tom Shimabukuro, MD, MPH, MBA

Immunization Safety Office (ISO)

Division of Healthcare Quality Promotion

National Center for Emerging and Zoonotic Infectious Diseases

Centers for Disease Control and Prevention (CDC)

National Vaccine Advisory Committee (NVAC)
September 9, 2014



Topics

- Background on VAERS
- VAERS 2.0 form (proposed)
- Activities and next steps

Vaccine Adverse Event Reporting System (VAERS)


- National spontaneous reporting system for adverse events after US-licensed vaccines
 - In recent years, received around 30,000 U.S. reports annually
 - Accepts reports from healthcare providers, manufacturers and the public
 - Signs/symptoms of adverse event coded (using MedDRA terms) and entered into database
- Jointly administered by CDC and FDA
- Authorized by National Childhood Vaccine Injury Act of 1986

Submitting a VAERS report (currently)

- Secure online submission (~30% of reports in recent years, but has plateaued)
- Mailed written hardcopy of paper form
- Faxed hardcopy
- Via telephone through a VAERS customer service representative

VAERS-1 report form*

- Paper form; must be completed by hand or using a typewriter
- Forms are mailed or faxed to VAERS contractor
- Requires manual receipt, processing and data entry procedures
- Hardcopies scanned and uploaded to the VAERS image database
- Resource intensive to manage paper reporting



*Online reporting form has same fields in a different presentation

Objectives for the VAERS 2.0 form (proposed)

- Create a fillable/savable electronic reporting form
- Update data fields to address current vaccine safety information needs and changes in vaccination practices over time
- Modernize the appearance and format of the VAERS form
- Modernize reporting procedures (implement electronic document upload capability with the VAERS 2.0 form)
- Ensure data collected on the VAERS 2.0 form allows for comparisons to be made with older data (i.e., historical comparisons between VAERS-1 and VAERS 2.0 data)

Why revise the VAERS form?

- □ Some fields on the current VAERS form (VAERS-1) have limited public health and/or regulatory value
 - Other important information isn't being collected
- Some fields are no longer relevant due to changes in the immunization program
- The language in some fields is confusing and needs clarification
- □ Fields used in paper reporting and for manual processing will no longer be necessary (e.g., manufacturer fields after the transition to the the ICH E2B(R3) message standard)
- □ Federal advisory committees and other stakeholders have expressed interest in collecting information on pregnancy status, race and ethnicity

Why revise the VAERS form? (cont.)

- □ Handwritten and mailed/faxed copies of paper reports is an inefficient way to conduct vaccine safety surveillance
- Paperless reporting using an electronic form would
 - Eliminate most manual processing and much data entry
 - Mitigate problems with poor handwriting and non-standard reporting
 - Take advantage of smart features (drop down menus, check boxes, pop-up instructions/reminders, logic checks)
 - Allow for standardized data elements (dates and times)
 - Address the complaint of getting "timed out" on the online reporting tool
- Manufacturers will be transiting to fully electronic reporting using the ICH E2B(R3) message standard

VAERS 2.0 form development

- Actions that have already occurred
 - Initial VAERS 2.0 development by CDC, FDA and VAERS contractor staff
 - Internal (CDC, FDA and VAERS contractor) review and revision; review and revision is an ongoing activity
 - Initial external review by immunization partners (CDC immunization program, NVPO, HRSA, DoD, ACIP liaison representatives, state immunization program officials, other partners)
 - Cognitive interviews with potential reporters (physicians, nurses, pharmacist, parents, patients)
 - Major revisions based on results of cognitive interviews
 - Presented to internal and selected external partners (CDC immunization program, state Vaccine Safety Coordinators, others)
 - Presented to the Federal Immunization Safety Task Force (ISTF)
 - Follow up interviews with a sample of individuals that completed cognitive interviews to test the revised form
 - Presented to the Advisory Commission on Childhood Vaccines (ACCV)

VAERS 2.0 electronic form reporting (proposed)

- 1. Reporter downloads the VAERS 2.0 form from the VAERS website
- 2. Reporter completes a VAERS 2.0 form on a computer (form is a fillable/savable PDF document)
- 3. Reporter saves the VAERS 2.0 report as an electronic document in a secure environment per instructions
- 4. Reporter uploads saved VAERS 2.0 report to the VAERS contractor through the VAERS website
- 5. VAERS contractor electronically extracts the data from the VAERS 2.0 report into the VAERS database (also reviews, redacts and performs Q&A on data)
- 6. VAERS contractor generates an individual report for the VAERS image database

VAERS-1 form (current)

www.vaers.hhs.gov/resources/v aers_form.pdf

WEBSITE: www	v.vaers.hhs.gov E-MA	IL: info@vaers.org	FAX: 1-877-721-0366			
VACCINE ADVERSE EVENT REPORTING SYSTEM 24 Hour Toll-Free Information 1-800-822-7967			For CDC/FDA Use Only			
), Rockville, MD 20849		VAERS Number			
VALKS PATIENT IDENTITY KEPT CONFIDENTIAL			Date Received			
Patient Name:	Vaccine administered	y (Name): Form completed by (Name):				
Last First M.I.	Responsible		Relation □ Vaccine Provider □ Patient/Parent			
	Physician		to Patient Manufacturer Other			
Address	Facility Name/Address	S	Address (if different from patient or provi	ider)		
City State Zip	City	State Zip	City State Zi	in		
,	Telephone no. ()					
Telephone no. ()	Telephone no. ()	1415				
State 2. County where administered	3. Date of birth	4. Patient age	5. Sex 6. Date form completed	<u>'</u>		
7. Describe adverse events(s) (symptoms, signs	·	if any	Check all appropriate:	уу		
Describe adverse events(s) (symptoms, signs	time course) and treatment	, ir any	Patient died (date/)			
			☐ Life threatening illness mm dd y ☐ Required emergency room/doctor visit	/y		
	☐ Required hospitalization (days)					
	☐ Resulted in prolongation of hospitalization ☐ Resulted in permanent disability					
			☐ None of the above			
9. Patient recovered YES NO UNKNOWN			10. Date of vaccination 11 Adverse even	t onset		
12. Relevant diagnostic tests/laboratory data						
	Time PM Time	,, AM PM				
13. Enter all vaccines given on date listed in no. 1)					
Massine (hype)	Lot number	No. Previous Route/Site Doses				
Vaccine (type) M.	Lot number	Houte/Site Doses				
b.						
C						
d.						
14. Any other vaccinations within 4 weeks prior to	the date listed in no. 10		No Provious Date			
Vaccine (type) Manufacturer	Lot number	Route/Site	No. Previous Date doses given			
a. — — — —						
b.———						
15. Vaccinated at:		ccine purchased with:	17. Other medications			
☐ Private doctor's office/hospital ☐ Military ☐ Public health clinic/hospital ☐ Other/ii	nds nown					
18. Illness at time of vaccination (specify)			birth defects, medical conditions (specify)			
		2				
20. Have you reported No	To health department		nly for children 5 and under			
this adverse event previously?	To manufacturer	22. Birth weight lb.	23. No. of brothers and sisters			
21. Adverse event following prior vaccination (chec			tted by manufacturer/immunization project			
Adverse Onset Ty		24. Mfr./imm. proj. report		į.		
□ In patient	III Selles					
☐ In brother		26. 15 day report?	27. Report type	27. Report type		
or sister		☐ Yes ☐ No	☐ Initial ☐ Follow-Up			
Health care providers and manufacturers are required by	y law (42 USC 300aa-25) to rep	I ort reactions to vaccines listed	in the Table of Reportable Events Following Immuni:	zation.		
Reports for reactions to other vaccines are	voluntary except when required	as a condition of immunization	grant awards.			

VAERS 2.0 form (proposed)

VAERS Vaccine Adverse Event Reporting Syst	em Items 2, 4, Patient iden		<mark>and 21</mark> are <mark>ESSENT</mark> Ifidential. Use <mark>Contin</mark>			sary.			
INFORMATION ABOUT THE PATIENT WH	O RECEIVED THE V	ACCINE	Use Continuation	Page (page	2) for nos. 9-12, it	f necessary			
1. Patient name: (First) (Last) Street address: City: State: County:	Prescriptions, over-the-counter medications, dietary supplements or herbal remedies being taken at time of vaccination:								
ZIP code: Tele: () Email:			es to medications, fo	od, or other	products: (Explain)				
2. Date of birth: (mm/dd/yyyy) 3. Sex: □ Male □ Fen	-								
4. Date and time of vaccination: (mm/dd/yyyy)			illness at the time of	accination	and up to one mont	th prior:			
5. Date and time adverse event started: (mm/dd/yyyy) Time: AM									
6. Age at vaccination: Years Months 7. Today's date: (mm/dd/yyyy)			12. Chronic or long-standing health conditions:						
8. Report is about vaccine administered to a pregnant woman: No or unknown (If Yes, describe pregnancy history, estimated date of delivery, birth weight if available, an									
INFORMATION ABOUT THE PERSON COMPLETING THIS FORM	INFO	DRMATION A	ABOUT FACILITY W	HERE VAC	CINE WAS GIVEN				
13. Form completed by: (Name)	15. Facility/clinio	15. Facility/clinic name: 16. Type of facility:							
Relation to patient: Healthcare professional/staff Patient (yourself)					☐ Doctor's office or hospital ☐ Pharmacy or drug store				
☐ Parent/guardian/caregiver ☐ Other:	Fax: ()	Fax: ()							
Street address: Check if same as no. 1	Street address:		Check if same as no. 13	Workplace clinic					
City: State: ZIP code:				☐ Public health clinic					
Tele: () Email:	City:				ng home or senior li				
14. Best doctor/healthcare Name:		State: ZIP code:			School/student health clinic				
professional to contact about the patient: Tele: ()Ext:	Tele: ()			☐ Other					
about the patient.	Email:			Unkno	own				
WHAT VACCINES WERE GIVEN? WHAT HA	PPENED TO THE PA	ATIENT? >	Use Continuation I	Page (page .	2) for nos. 17-19, ii	f necessary			
17. Enter all vaccines given on date listed in no. 4: (Route is HOW vaccine was given, b	ody site is WHERE vac				Dadu sies	Dose no.			
Vaccine (type and brand name) Manufacturer		Lot numb	ner Route		Body site	in series			
			_						
18. Describe event(s), treatment and outcome(s), if any: (symptoms, signs, time course	e, etc.,)	21. Result or outcome of event: (Check all that apply) Doctor or other healthcare professional office/clinic visit							
		Emergency room or emergency department visit				IIIC VISIL			
			☐ Hospitalization: Number of days(if known)						
			Hospital name:		13				
			City:		State:				
		ı	Prolongation of ex						
			/Vaccine received du ☐ Life threetening ill	-	nospitalization)				
19. Medical tests and laboratory results related to event(s): (Include dates)			☐ Life threatening illness☐ Disability or permanent damage						
,			☐ Patient died: Date of death						
			Congenital anomaly or birth defect						
20. Patient has recovered from event: Yes No Unknown			□ None of the above						
			Use Continuation l		2) for nos. 22-23, ii	f necessary			
Any other vaccines received within one month prior to the date listed in no. 4: / Vaccine (type and brand name) Manufacturer	(Route is HOW vaccine	Lot numb		e was given)	Body site	Dose no.			
Vaccine (type and brand name) Manufacturer		LOT HUME	per houte		Dody Site	III ZELIEZ			
20 11 12 12 12 12 12 12 12 12 12 12 12 12									
23. Has the patient ever had an adverse event following any previous vaccine: (If yo	es, describe and include	e patient age, v	raccination dates, and va	occine type a	nd brand name)				
		442		Marke 11		90-1-1-1			
24. Patient's race: American Indian or Alaska Native Asian (Check all that apply) White Unkno	or African American Native Hawaiian or Other Pacific Islander								
FOR U.S. MILITARY/DEPT OF DEFENSE (DoD) RELATED REPORTS (Complete only if applicable)									
27. Status at time of vaccination: Active duty Reserve National Guard Other: 28. Vaccinated at Military/DoD site: Yes No									

FORM FDA VAERS-2.0 (1/15) Use Continuation Page (page 2) if necessary. Page 1 of 2

Next steps

- 1. Present the VAERS 2.0 form to NVAC and ACIP
- 2. Create "smart" electronic form
- 3. Computer test form with potential reporters
- 4. Public comment solicitation through Federal Register
- 5. Make final revisions based on computer testing results and comments
- 6. Develop the platform to accept electronic VAERS 2.0 submissions and update the online reporting tool
- 7. Implement the VAERS 2.0 form
- 8. Evaluate completeness and quality of VAERS data (pre-post comparison)



Centers for Disease Control and Prevention Atlanta, GA



Thank You

For more information please contact Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA 30333

Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348

E-mail: cdcinfo@cdc.gov Web: www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

